Version 1.5, revision planned in 2011.

Last revised in November 2007

June 2010 — updated to include the option of using febuxostat for the management of chronic gout for people who are intolerant of allopurinol, or for whom allopurinol is contraindicated. This is in line with National Institute for Health and Clinical Excellence technology appraisal guidance Febuxostat for the management of hyperuricaemia in people with gout [NICE, 2008]. In addition, in people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line NSAIDs. Issued in July 2010.

December 2009 — minor update. Triamcinolone acetonide (Kenalog^®) pre-filled syringes have been discontinued. Prescription replaced with triamcinolone acetonide 40 mg/1 mL vials. Issued in December 2009.

July to November 2007 — converted from PRODIGY guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.

The recommendations have been revised to be in-line with the British Society for Rheumatology and the British Health Professionals guidelines for the management of gout published in 2007. The dose and duration of recommended drug treatments have been updated to be in-line with current practice, in particular, for oral prednisolone.